Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Enrolling by invitation Phase 3 Interventional

An Evaluation of the Long-Term Safety and Efficacy of TSND-201 for the Treatment of PTSD

ClinicalTrials.gov ID: NCT07670702

Public ClinicalTrials.gov record NCT07670702. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Open-Label Extension Study to Assess the Long-term Safety and Efficacy of TSND-201 for the Treatment of PTSD

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is evaluating the long-term safety and efficacy of TSND-201 in adults with PTSD. Participants that have completed a double-blind clinical trial with TNSD-201 for PTSD will be invited to participate in this open-label extension trial. Each participant will be able to receive up to three Treatment Courses over the duration of the study (up to 48 weeks). Each Treatment Course includes 4 dosing sessions, spaced one week apart.

Study identification

NCT ID
NCT07670702
Recruitment status
Enrolling by invitation
Study type
Interventional
Phase
Phase 3
Lead sponsor
Transcend Therapeutics
Industry
Enrollment
300 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
Not listed
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 21, 2026
Primary completion
Nov 30, 2028
Completion
Dec 31, 2028
Last update posted
Sep 3, 2026

2026 – 2029

United States locations

U.S. sites
17
U.S. states
11
U.S. cities
17
Facility City State ZIP Site status
Preferred Research Partners Little Rock Arkansas 72211
CalNeuro Research Group Los Angeles California 90025
Catalina Research Institute Montclair California 91763
Starlight Clinical Research Evergreen Colorado 80439
Clinical Neuroscience Solutions - Jacksonville Jacksonville Florida 32256
Segal Trials Lauderhill Florida 33319
Accel Clinical Research Maitland Florida 32751
CNS Healthcare Orlando Florida 32801
Vitalix Clinical Worcester Massachusetts 01608
Arch Clinical Trials Creve Coeur Missouri 63141
Bio Behavioral Health Toms River New Jersey 08755
Insight Clinical Trials Independence Ohio 44131
Flourish Research Plymouth Meeting Pennsylvania 19462
Austin Clinical Trial Partners Austin Texas 78737
Haracec Clinical Research El Paso Texas 79902
Cedar Clinical Research Draper Utah 84020
Inner Space Research Orem Utah 84058

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07670702, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 3, 2026 · Synced Sep 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07670702 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →